{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:56:51Z","timestamp":1793048211438,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD. Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin\/kexin type 9 (PCSK9) gene expression and reduces LDL-C levels with only two or three injections per year. This review summarizes the mechanism, efficacy, safety, and applications of Inclisiran in various populations and settings, based on recent literature. It also compares Inclisiran with other lipid-lowering drugs, especially other PCSK9 inhibitors. We conclude that Inclisiran is a promising lipid-lowering agent that can provide convenience and effectiveness for patients with high cardiovascular risk. However, some challenges and limitations remain for Inclisiran, such as its long-term safety and efficacy, its cost-effectiveness and accessibility, and its interactions and synergies with other drugs. These issues need further investigation and evaluation in future studies.<\/jats:p>","DOI":"10.3389\/fphar.2023.1260921","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T03:39:05Z","timestamp":1697168345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Inclisiran: a new generation of lipid-lowering siRNA therapeutic"],"prefix":"10.3389","volume":"14","author":[{"given":"Yanzhen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaigang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115880","article-title":"Pcsk9 biology and its role in atherothrombosis","volume":"22","author":"Barale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2217\/fca-2020-0150","article-title":"Clinical implications and outcomes of the orion phase iii trials","volume":"17","author":"Brandts","year":"2021","journal-title":"Future Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40256-022-00534-9","article-title":"Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis","volume":"22","author":"Desai","year":"2022","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/2047487320941987","article-title":"Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the odyssey outcomes trial","volume":"28","author":"Diaz","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.numecd.2021.11.012","article-title":"Cardiovascular disease burden attributable to dietary risk factors from 1990 to 2019: a systematic analysis of the global burden of disease study","volume":"32","author":"Dong","year":"2022","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"key":"B6","first-page":"2459","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume-title":"Eur. Heart. J.","author":"Ference","year":"2013"},{"key":"B7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable rnai therapeutic inhibitor of pcsk9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40259-019-00399-6","article-title":"Small interfering rna therapeutic inclisiran: a new approach to targeting pcsk9","volume":"34","author":"German","year":"2020","journal-title":"Biodrugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40256-021-00477-7","article-title":"A critical review of the efficacy and safety of inclisiran","volume":"21","author":"Hardy","year":"2021","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic sirna: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e16664","DOI":"10.7759\/cureus.16664","article-title":"Can clinicians start prescribing inclisiran for hypercholesterolemia today? A review of clinical studies for internal medicine physicians and endocrinologists","volume":"13","author":"Jahangir","year":"2021","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"Effect of alirocumab on stroke in odyssey outcomes","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_20_20","article-title":"Pcsk9 monoclonal antibodies: an overview","volume":"21","author":"Kaddoura","year":"2020","journal-title":"Heart Views"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics - a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6030063","article-title":"Inclisiran: a new promising agent in the management of hypercholesterolemia","volume":"6","author":"Kosmas","year":"2018","journal-title":"Diseases"},{"key":"B16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dc18-1491","article-title":"Inclisiran lowers ldl-c and pcsk9 irrespective of diabetes status: the orion-1 randomized clinical trial","volume":"42","author":"Leiter","year":"2019","journal-title":"Diabetes Care"},{"key":"B17","volume-title":"Association between low density lipoprotein cholesterol and all-cause mortality: results from the nhanes 1999\u20132014","author":"Liu","year":"2021"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2127573","DOI":"10.1001\/jamanetworkopen.2021.27573","article-title":"Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China","volume":"4","author":"Lu","year":"2021","journal-title":"Jama Netw. Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2023.04.010","article-title":"The clinical effects of inclisiran, a first-in-class ldl-c lowering sirna therapy, on the ldl-c levels in Chinese patients with hypercholesterolemia","volume":"2023","author":"Luo","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fimmu.2017.00331","article-title":"Rna interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"8129513","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting pcsk9-a narrative review","volume":"2022","author":"Mercep","year":"2022","journal-title":"Cardiovasc Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11883-021-00936-1","article-title":"The role of rna-targeted therapeutics to reduce ascvd risk: what have we learned recently?","volume":"23","author":"Miname","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","article-title":"Elevated ldl cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort","volume":"396","author":"Mortensen","year":"2020","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated ldl cholesterol (orion-3): results from the 4-year open-label extension of the orion-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated ldl cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of pcsk9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e9778","DOI":"10.1161\/JAHA.118.009778","article-title":"Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life","volume":"7","author":"Robinson","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"Pcsk9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"112227","DOI":"10.1016\/j.biopha.2021.112227","article-title":"Inclisiran in lipid management: a literature overview and future perspectives","volume":"143","author":"Scicchitano","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12933-020-01185-3","article-title":"Association of circulating proprotein convertase subtilisin\/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study","volume":"19","author":"Shi","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-pcsk9 antibody effectively lowers cholesterol in patients with statin intolerance: the gauss-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.numecd.2011.06.002","article-title":"Proprotein convertase subtilisin\/kexin type 9 (pcsk9): from structure-function relation to therapeutic inhibition","volume":"21","author":"Tibolla","year":"2011","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the orion-7 and orion-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1260921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T03:39:08Z","timestamp":1697168348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1260921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":36,"alternative-id":["10.3389\/fphar.2023.1260921"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1260921","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"article-number":"1260921"}}